{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:07:32Z","timestamp":1792886852763,"version":"4.5.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.2215\/cjn.08611209","type":"journal-article","created":{"date-parts":[[2010,5,24]],"date-time":"2010-05-24T23:45:03Z","timestamp":1274744703000},"page":"1330-1339","source":"Crossref","is-referenced-by-count":58,"title":["Renin-Angiotensin-Aldosterone System Blockade Effects on the Kidney in the Elderly"],"prefix":"10.2215","volume":"5","author":[{"given":"Faruk","family":"Turgut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasheed A.","family":"Balogun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emaad M.","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-24-20230601","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"R3-24-20230601","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1532-5415.2007.01215.x","article-title":"Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: Data from the National Health and Nutrition Examination Survey 1988 to 2004","volume":"55","author":"Ostchega","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"R4-24-20230601","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1001\/archinternmed.2007.35","article-title":"The growing burden of diabetes mellitus in the US elderly population","volume":"168","author":"Sloan","year":"2008","journal-title":"Arch Intern Med"},{"key":"R5-24-20230601","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"R7-24-20230601","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R8-24-20230601","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2006.01.059","article-title":"Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease","volume":"98","author":"Ferrario","year":"2006","journal-title":"Am J Cardiol"},{"key":"R9-24-20230601","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1681\/ASN.2006040356","article-title":"Renin-angiotensin-aldosterone system and progression of renal disease","volume":"17","author":"R\u00fcster","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R10-24-20230601","doi-asserted-by":"crossref","first-page":"R1473","DOI":"10.1152\/ajpregu.90699.2008","article-title":"Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors","volume":"295","author":"Abdel-Rahman","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R11-24-20230601","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review","volume":"329","author":"Strippoli","year":"2004","journal-title":"BMJ"},{"key":"R12-24-20230601","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R13-24-20230601","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7326\/0003-4819-148-1-200801010-00189","article-title":"Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension","volume":"148","author":"Matchar","year":"2008","journal-title":"Ann Intern Med"},{"key":"R14-24-20230601","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R15-24-20230601","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1681\/ASN.2005121324","article-title":"Prevention and treatment of diabetic renal disease in type 2 diabetes: The BENEDICT study","volume":"17","author":"Remuzzi","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R16-24-20230601","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-0115(99)00027-0","article-title":"Angiotensin II and nitric oxide: A question of balance","volume":"81","author":"Millatt","year":"1999","journal-title":"Regul Pept"},{"key":"R17-24-20230601","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0002-9343(76)90888-3","article-title":"The biochemistry of the renin-angiotensin system and its role in hypertension","volume":"60","author":"Skeggs","year":"1976","journal-title":"Am J Med"},{"key":"R18-24-20230601","doi-asserted-by":"crossref","first-page":"H2337","DOI":"10.1152\/ajpheart.2001.281.6.H2337","article-title":"Angiotensin receptors: Signaling, vascular pathophysiology, and interactions with ceramide","volume":"281","author":"Berry","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R19-24-20230601","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1100\/tsw.2005.92","article-title":"Angiotensin II and renal tubular ion transport","volume":"5","author":"Valles","year":"2005","journal-title":"ScientificWorldJournal"},{"key":"R22-24-20230601","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/ndt\/13.suppl_7.25","article-title":"Acute renal failure of medical type in an elderly population","volume":"13","author":"Baraldi","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"R23-24-20230601","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(83)90977-7","article-title":"Essential hypertension in the elderly: Haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels","volume":"2","author":"Messerli","year":"1983","journal-title":"Lancet"},{"key":"R25-24-20230601","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1093\/ndt\/gfp357","article-title":"Prevalence of ambulatory hypotension in elderly patients with CKD stages 3 and 4","volume":"24","author":"Tomlinson","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R26-24-20230601","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199606203342507","article-title":"Angiotensin receptors and their antagonists","volume":"334","author":"Goodfriend","year":"1996","journal-title":"N Engl J Med"},{"key":"R27-24-20230601","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"key":"R28-24-20230601","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R29-24-20230601","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"R31-24-20230601","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med"},{"key":"R32-24-20230601","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0149-2918(00)83064-7","article-title":"A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension","volume":"22","author":"Lacourci\u00e8re","year":"2000","journal-title":"Clin Ther"},{"key":"R33-24-20230601","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older.","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"R34-24-20230601","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"key":"R35-24-20230601","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1751-7176.2009.00147.x","article-title":"The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older","volume":"11","author":"Kereiakes","year":"2009","journal-title":"J Clin Hypertens (Greenwich"},{"key":"R36-24-20230601","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/0002512-200926010-00005","article-title":"Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension: Efficacy and safety data from clinical trials","volume":"26","author":"Heagerty","year":"2009","journal-title":"Drugs Aging"},{"key":"R37-24-20230601","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"R38-24-20230601","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"R39-24-20230601","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.2337\/dc06-0570","article-title":"Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes","volume":"29","author":"Winkelmayer","year":"2006","journal-title":"Diabetes Care"},{"key":"R41-24-20230601","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"R42-24-20230601","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.07821109","article-title":"Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors","volume":"5","author":"Weir","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R43-24-20230601","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"R44-24-20230601","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1074-5521(00)00134-4","article-title":"Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin","volume":"7","author":"Rahuel","year":"2000","journal-title":"Chem Biol"},{"key":"R45-24-20230601","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","article-title":"Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension","volume":"49","author":"Oh","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R46-24-20230601","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.HYP.0000253780.36691.4f","article-title":"Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker","volume":"49","author":"O'Brien","year":"2007","journal-title":"Hypertension"},{"key":"R47-24-20230601","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation"},{"key":"R48-24-20230601","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"},{"key":"R49-24-20230601","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/08037050701717014","article-title":"Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension","volume":"16","author":"Verdecchia","year":"2007","journal-title":"Blood Press"},{"key":"R51-24-20230601","doi-asserted-by":"crossref","first-page":"S886","DOI":"10.1161\/circ.118.suppl_18.S_886-c","article-title":"Abstract 4423: The AGELESS Study: The effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients \u2265 65 years of age with systolic hypertension [Abstract]","volume":"118","author":"Duprez","year":"2008","journal-title":"Circulation"},{"key":"R52-24-20230601","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.107.750745","article-title":"Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: A 12-month randomized, double-blind comparator trial with hydrochlorothiazide","volume":"119","author":"Schmieder","year":"2009","journal-title":"Circulation"},{"key":"R53-24-20230601","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/147323000102900103","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"29","author":"Sato","year":"2001","journal-title":"J Int Med Res"},{"key":"R54-24-20230601","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"R55-24-20230601","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R56-24-20230601","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R57-24-20230601","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","article-title":"How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?","volume":"10","author":"Svensson","year":"2004","journal-title":"J Card Fail"},{"key":"R58-24-20230601","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ahj.2004.10.005","article-title":"Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure","volume":"148","author":"Tamirisa","year":"2004","journal-title":"Am Heart J"},{"key":"R59-24-20230601","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ahj.2009.07.003","article-title":"The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction","volume":"158","author":"Gheorghiade","year":"2009","journal-title":"Am Heart J"},{"key":"R60-24-20230601","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/archinte.163.13.1543","article-title":"Symptoms and the distress they cause: Comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension","volume":"163","author":"Hollenberg","year":"2003","journal-title":"Arch Intern Med"},{"key":"R61-24-20230601","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/BF02877769","article-title":"Probrain natriuretic peptide for assessment of efficacy in heart failure treatment","volume":"24","author":"Ozkara","year":"2007","journal-title":"Adv Ther"},{"key":"R62-24-20230601","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","article-title":"Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy","volume":"16","author":"Sato","year":"2003","journal-title":"Am J Hypertens"},{"key":"R63-24-20230601","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.HYP.32.3.387","article-title":"Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system","volume":"32","author":"Hollenberg","year":"1998","journal-title":"Hypertension"},{"key":"R64-24-20230601","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trials","volume":"167","author":"Phillips","year":"2007","journal-title":"Arch Intern Med"},{"key":"R65-24-20230601","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"R66-24-20230601","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"R67-24-20230601","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/HJH.0b013e328277596e","article-title":"Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus","volume":"25","author":"Hollenberg","year":"2007","journal-title":"J Hypertens"},{"key":"R68-24-20230601","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1755.2002.00536.x","article-title":"Dual renin-angiotensin system blockade at optimal doses for proteinuria","volume":"62","author":"Laverman","year":"2002","journal-title":"Kidney Int"},{"key":"R70-24-20230601","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R71-24-20230601","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","article-title":"Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: An analysis of 25 cases","volume":"110","author":"Schepkens","year":"2001","journal-title":"Am J Med"},{"key":"R72-24-20230601","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11606-009-1228-x","article-title":"Diabetes and drug-associated hyperkalemia: Effect of potassium monitoring","volume":"25","author":"Raebel","year":"2010","journal-title":"J Gen Intern Med"},{"key":"R73-24-20230601","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/hy09t1.096184","article-title":"ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis","volume":"38","author":"Segura","year":"2001","journal-title":"Hypertension"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201007000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:42Z","timestamp":1786369182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201007000-00024"}},"subtitle":["Benefits and Limitations"],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.08611209","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}